Spain joins genetics and ethics debate
This article was originally published in Clinica
Spain has joined in the genetics and ethics debate that has reached various stages in several other EU countries (see, for example, this issue, page 7). The government has wanted to appease urgent calls for changes in the law, but accepts the need for further debate, in the light of technological developments in this area.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.